Medical Resource Utilization Costs Research Articles

HSD27 Constrained Optimization Model to Estimate Best Booster Allocation Strategy to Minimize Hospital Bed-Days Under a Fixed Healthcare Budget

COVID-19 vaccine boosters are available in many countries. Public health policymakers face difficult choices over which booster brand to recommend, given limited budgets and the need to maximize health gains. Here, we provide a conceptual model to identify the best booster strategies for age-identified subpopulations under different conditions. A constrained optimization model with an objective function to minimize bed-days was developed that varied population proportion receiving different booster options by age, to identify the best booster strategy that minimized bed-days with a constraint of maximum healthcare expenditure of US$2.10/person. It included a 3-month decision-tree model to calculate bed-days, with the following health states: healthy/asymptomatic; mild (not hospitalized); moderate (general ward); severe (intensive care unit [ICU], no mechanical ventilation); critical (requiring mechanical ventilation); and death. Medical resource utilization (MRU) costs and hospital bed-days were calculated for each health state. The base country was Brazil. Three booster options, B1 (US$1), B2 (US$2), and no-booster (NB, US$0) were considered. Based on real-world effectiveness estimates, B1 and B2 were assumed to be 55% and 75% effective against mild/moderate COVID-19, respectively. Both reduced severe/critical COVID-19 by 90%. The target population was adults eligible for boosters, stratified by age. The best booster strategy identified recommended 100% coverage of those eligible, with B1 for population <70 years and B2 for population ≥70 years. Compared with NB, bed-days were reduced by 75%, hospitalizations by 68%, and ICU admissions by 90% leading to a 60% reduction in total costs (81% reduction in MRU costs). Within individual age-groups, costs were reduced by 57%-66% based on the age-specific disease risk. A constrained optimization model identifies the best age-specific booster allocation strategy to minimize hospital bed-days across different age groups without exceeding a predefined budget. Decision-makers could use this method to achieve the best possible health outcomes when healthcare resources are limited.

An Economic Comparison of Treatment Strategies with Anakinra in Systemic Juvenile Idiopathic Arthritis (sJIA).

IntroductionSystemic juvenile idiopathic arthritis (sJIA) is a rare, complex autoinflammatory disease with substantial morbidity, often characterized by fever, rash, and muscle pain, amongst other symptoms. Biologic agents, such as anakinra, have been successfully used to treat patients internationally, but their usage in some regions is limited to patients that have failed to achieve clinically inactive disease with corticosteroids and conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). Use of anakinra early in the disease course leads to better clinical outcomes; however, longer-term costs for this treatment strategy have not been established. This study compares the economic implications of first-line versus later-line availability of anakinra for patients with sJIA.MethodsData for patients treated with first-line anakinra were identified from a single-center, prospective study and compared to a combination of published trial and economic evaluation information to facilitate a comparison to later-line anakinra (ie, following corticosteroids + csDMARDs). Costs were estimated for product acquisition and medical resource utilization (MRU), including planned outpatient visits and unplanned hospital admissions. Total costs over a 5-year horizon were compared.ResultsTotal 5-year product acquisition cost for the first-line anakinra strategy was €24,021, and for later-line anakinra was €20,471. The corresponding MRU costs were €19,197 (first-line) versus €25,425 (later-line). Overall 5-year costs (product acquisition and MRU) were lower for the first-line strategy (€43,218 versus €45,896).ConclusionThe use of anakinra for patients with sJIA in the first-line setting is efficacious to induce and sustain inactive disease, and the findings of this study show that this treatment strategy leads to cost savings through reduced medical expenditure.